Abstract
Understanding the relationship between insight, depression, and suicidality in first-episode psychosis (FEP) is crucial for improving clinical outcomes and preventing suicide during early treatment stages. This longitudinal cohort study examined 264 participants enrolled in coordinated specialty care (CSC) services for FEP to investigate how insight and depression at admission impact suicidality at 6 and 12 months, assess depression’s mediating role between insight and suicidality, and evaluate the persistence of depression over time. Regression analyses assessed the relationships among these variables, while mediation analyses explored depression’s mediating effect. Significant predictors of suicidality at 6 months included insight (OR 0.71, 95% CI: 0.53 - 0.94), depression (OR 5.40, 95% CI: 2.45 - 12.61), and previous suicide attempts (OR 2.91, 95% CI: 1.21 - 7.00). At 12 months, insight (OR 0.70, 95% CI: 0.52 - 0.92) and depression (OR 2.82, 95% CI: 1.26 - 6.50) remained significant. Depression mediated 27.32% of the effect of insight on suicidality at 6 months and 19.76% at 12 months. Despite a general decrease in depressive symptoms, a subset of participants remained persistently depressed. The study highlights the significant mediating role of depression in the relationship between insight and suicidality, with depression emerging as the strongest predictor of suicidality. Early detection and treatment of depression in FEP should be prioritized, and further research should focus on targeted interventions within CSC.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by National Institutes of Health (R01MH103831) and the Gustavus and Louise Pfeiffer Research Foundation. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. This work was also funded by the State of Connecticut, Department of Mental Health and Addiction Services, but this publication does not express the views of the Department of Mental Health and Addition Services or the State of Connecticut. The views and opinions expressed are those of the authors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of the Institutional Review Boards of Yale University, Beth Israel Deaconess Medical Center, and the Massachusetts Department of Mental Health gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
